4D Molecular Therapeutics Has $375 Million To Support Its Retinal Drug Trials
Management expects cash and collaboration payments to cover operations at least into the second half of 2028, beyond planned 2027 trial results.
4D Molecular Therapeutics, which is testing genetic treatments for retinal diseases, reported $375 million in cash and investments Thursday in its SEC earnings filing. Management expects that money and anticipated collaboration payments to finance operations at least into the second half of 2028, beyond its expected 2027 late-stage trial results.
Otsuka Payments Help Fund Testing
The cash balance was measured at September 30, compared with $514 million at the end of 2025. The company's funding estimate includes expected payments from Otsuka Pharmaceutical, its collaboration partner, and covers operating costs and capital spending under its current plan.
Research spending rose to $69.8 million in the third quarter from $49.4 million a year earlier. The company attributed the increase mainly to late-stage trials of 4D-150 for wet age-related macular degeneration.
Collaboration and licensing revenue reached $4.1 million, against $0.1 million a year earlier. The company credited mainly Otsuka's sharing of clinical-trial costs and reimbursements. Administrative spending increased to $15.6 million from $11.8 million.
The quarterly net loss widened to $78.1 million from $56.9 million, with the per-share loss reaching $1.08 versus $1.01. For the first nine months, the company lost $219.8 million, compared with $159.5 million a year earlier.
Retinal Results Due In 2027
4D-150 is designed to deliver medicines that control retinal disease over multiple years through a single eye injection, with the aim of reducing repeated treatments. The company has no marketed products; it develops genetic medicines using engineered viral delivery vehicles, with programs focused on the retina and lungs.
Its North American wet-AMD trial completed enrollment in February and randomization in March, with 523 participants. The global trial finished enrollment in June and randomization in August, with 531 participants. Management expects results in the second quarter and second half of 2027, respectively.
David Kirn, 4D Molecular Therapeutics' co-founder, president and chief executive, described 2027 as a year “which we anticipate will be a transformative year for the Company following expected topline readouts from both 4FRONT Phase 3 trials in wet AMD.”
The company had already announced on September 28 that its late-stage diabetic-macular-edema trial began enrolling patients at multiple sites. That study plans 514 participants and compares 4D-150 with aflibercept, testing vision changes at 52 weeks and whether patients need fewer injections.
Regulatory Hire And Lung Programs
Eric Floyd joined as chief regulatory and quality officer, overseeing regulatory strategy, engagement with authorities and quality work. He previously held chief regulatory officer roles at Silence Therapeutics and Neurogene, and senior regulatory or quality positions at Merck, Sanofi and Novartis.
The company expects a year-end trial and program update for 4D-710, its experimental cystic-fibrosis treatment. It also continues to evaluate taking 4D-175, its geographic-atrophy candidate, into human testing.
The expected wet-AMD readouts in 2027 are the next late-stage tests for 4D-150; management's funding projection extends at least into the second half of 2028.
Sources
- 8-K Filing — 4D Molecular Therapeutics, Inc. (FDMT) — SEC EDGAR
- Exhibit fdmt-ex99_1.htm — 4D Molecular Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- 8-K filed 2026-09-28 — 4D Molecular Therapeutics, Inc. (earlier disclosure) — SEC EDGAR